Refile: Neuronetics Q4 revenue rises, appoints Dan Reuvers as CEO

Neuronetics

17/03/2026 12:02

Corrects spelling of "appoints" in headline

Overview

US medical technology firm's Q4 revenue grew 86% yr/yr, driven by Greenbrook clinic acquisition

Gross margin for Q4 fell to 52% from 66% due to clinic business inclusion

Company appointed Dan Reuvers as CEO, effective March 23, 2026

Outlook

Neuronetics expects Q1 2026 revenue between $33 mln and $35 mln

Company sees full-year 2026 revenue of $160 mln to $166 mln

Neuronetics expects 2026 gross margin of 47% to 49% and operating expenses of $100 mln to $105 mln

Result Drivers

GREENBROOK ACQUISITION - Q4 revenue growth was primarily driven by the addition of Greenbrook clinic revenue following the December 2024 acquisition

SYSTEM SALES - U.S. NeuroStar Advanced Therapy System revenue rose 15% in Q4, with 49 systems shipped

GROSS MARGIN PRESSURE - Gross margin declined to 52% from 66.2%, mainly due to the inclusion of Greenbrook’s clinic business

Company press release: ID:nGNX6lF96z

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.10
Q4 Gross Margin
52.00%
Q4 Operating Expenses
$26.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Neuronetics Inc is $7.00, about 414.7% above its March 16 closing price of $1.36

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)